Tara Reshadmanesh
Overview
Explore the profile of Tara Reshadmanesh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Javanmardi E, Reshadmanesh T, Gohari S, Behnoush A, Ahangar H
Health Sci Rep
. 2025 Jan;
8(1):e70354.
PMID: 39831078
Background And Aims: Bendopnea is a symptom found in patients with heart failure (HF) defined as shortness of breath when bending forward. The present study examined the correlation between bendopnea...
2.
Reshadmanesh T, Behnoush A, Farajollahi M, Khalaji A, Ghondaghsaz E, Ahangar H
Clin Cardiol
. 2024 Jul;
47(7):e24315.
PMID: 38961752
Background: Calprotectin, also known as MRP8/14, is generated by immune cells and is altered in several inflammatory diseases. Studies have assessed their levels in patients with coronary artery disease (CAD)...
3.
Ghanbari S, Gohari S, Reshadmanesh T, Mahjani M, Arsang-Jang S, Ismail-Beigi F, et al.
J Diabetes Metab Disord
. 2024 Jun;
23(1):1107-1111.
PMID: 38932825
Background: Sodium glucose co-transporter2 (SGLT2) inhibitors have exhibited cardioprotective properties in diabetes patients. The aim of this study was to investigate the effect of Empagliflozin on changes in echocardiographic parameters....
4.
Behnoush A, Parmis Maroufi S, Reshadmanesh T, Kia Y, Norouzi M, Mohammadi S, et al.
BMC Gastroenterol
. 2024 Mar;
24(1):107.
PMID: 38486190
Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic relapsing-remitting systemic disease of the gastrointestinal tract with rising incidence. Studies have shown that...
5.
Taheri H, Chiti H, Reshadmanesh T, Gohari S, Jalilvand A, Arsang-Jang S, et al.
J Diabetes Metab Disord
. 2023 Nov;
22(2):1723-1730.
PMID: 37975102
Background: Empagliflozin is a sodium glucose cotransporter-2 (SGLT2) inhibitor that has been suggested to improve cardiac function and vascular recovery. The risk of coronary artery diseases is much higher in...
6.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, et al.
Diabetol Metab Syndr
. 2022 Nov;
14(1):170.
PMID: 36397128
Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet...
7.
Gohari S, Reshadmanesh T, Khodabandehloo H, Fathi M, Ahangar H, Arsang-Jang S, et al.
BMC Cardiovasc Disord
. 2021 Jul;
21(1):318.
PMID: 34193056
Background: Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM)....
8.
Noohi Bezanjani F, Gohari S, Bassiri H, Ahangar H, Reshadmanesh T
Arch Iran Med
. 2020 Sep;
23(9):600-604.
PMID: 32979906
Background: Thrombotic and thromboembolic events are important causes of mortality and morbidity in patients with prosthetic heart valve. The aim of this study is to evaluate the factors that may...
9.
Masoumkhani F, Gohari S, Reshadmanesh T, Ahangar H, Faghihzadeh S
Minerva Cardiol Angiol
. 2020 Jun;
69(2):133-140.
PMID: 32492986
Background: The aim of this study was to evaluate the relationship between the early/late complete ST-resolution and short-term cardiovascular outcomes in patients undergoing primary angioplasty. Methods: This was a prospective...